Paper41006418
Identification of novel small molecule inhibitors targeting multiple methyltransferase like proteins against hepatocellular carcinoma.
Morshed MN and 8 others. Sci Rep, 2025. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Identification of novel small molecule inhibitors targeting multiple methyltransferase like proteins against hepatocellular carcinoma. Papers, record 41006418. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41006418
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Identification of novel small molecule inhibitors targeting multiple methyltransferase like proteins against hepatocellular carcinoma.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Methyltransferases | Major topic |
| Enzyme Inhibitors | Major topic |
| Antineoplastic Agents | Major topic |
| Small Molecule Libraries | Major topic |
| Humans | |
| Cell Proliferation | |
| Cell Line, Tumor | |
| Hep G2 Cells | |
| Molecular Dynamics Simulation |
Source PubMed
References71
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35961526 | Microtubule-affinity regulating kinase 4: A potential drug target for cancer therapy. | Cell Signal | 2022 | https://conductscience.org/library/papers/35961526 | PubMed |
| 2 | 35784404 | Novel roles of METTL1/WDR4 in tumor via m7G methylation. | Mol Ther Oncolytics | 2022 | https://conductscience.org/library/papers/35784404 | PubMed |
| 3 | 34285249 | Multi-omics integration of methyltransferase-like protein family reveals clinical outcomes and functional signatures in human cancer. | Sci Rep | 2021 | https://conductscience.org/library/papers/34285249 | PubMed |
| 4 | 35429902 | TSPAN31 regulates the proliferation, migration, and apoptosis of gastric cancer cells through the METTL1/CCT2 pathway. | Transl Oncol | 2022 | https://conductscience.org/library/papers/35429902 | PubMed |
| 5 | 34431664 | 1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors. | J Med Chem | 2021 | https://conductscience.org/library/papers/34431664 | PubMed |
| 6 | 32834109 | DFT studies on vibrational and electronic spectra, HOMO-LUMO, MEP, HOMA, NBO and molecular docking analysis of benzyl-3-N-(2,4,5-trimethoxyphenylmethylene)hydrazinecarbodithioate. | J Mol Struct | 2020 | https://conductscience.org/library/papers/32834109 | PubMed |
| 7 | 22553363 | ZINCPharmer: pharmacophore search of the ZINC database. | Nucleic Acids Res | 2012 | https://conductscience.org/library/papers/22553363 | PubMed |
| 8 | 31463732 | METTL1 overexpression is correlated with poor prognosis and promotes hepatocellular carcinoma via PTEN. | J Mol Med (Berl) | 2019 | https://conductscience.org/library/papers/31463732 | PubMed |
| 9 | 17016424 | Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Nat Rev Drug Discov | 2006 | https://conductscience.org/library/papers/17016424 | PubMed |
| 10 | 34452630 | DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. | Clin Epigenetics | 2021 | https://conductscience.org/library/papers/34452630 | PubMed |
| 11 | 34790902 | Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. | Nat Cancer | 2021 | https://conductscience.org/library/papers/34790902 | PubMed |
| 12 | 34623518 | Molecular classification of hepatocellular carcinoma: prognostic importance and clinical applications. | J Cancer Res Clin Oncol | 2022 | https://conductscience.org/library/papers/34623518 | PubMed |
| 13 | 33151290 | PubChem in 2021: new data content and improved web interfaces. | Nucleic Acids Res | 2021 | https://conductscience.org/library/papers/33151290 | PubMed |
| 14 | 32508653 | Discovering Anti-Cancer Drugs via Computational Methods. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/32508653 | PubMed |
| 15 | 32068977 | METTL3 expression is associated with glycolysis metabolism and sensitivity to glycolytic stress in hepatocellular carcinoma. | Cancer Med | 2020 | https://conductscience.org/library/papers/32068977 | PubMed |
| 16 | 16578791 | Absolute electronegativity and hardness correlated with molecular orbital theory. | Proc Natl Acad Sci U S A | 1986 | https://conductscience.org/library/papers/16578791 | PubMed |
| 17 | 18424800 | PharmaGist: a webserver for ligand-based pharmacophore detection. | Nucleic Acids Res | 2008 | https://conductscience.org/library/papers/18424800 | PubMed |
| 18 | 36408920 | UniProt: the Universal Protein Knowledgebase in 2023. | Nucleic Acids Res | 2023 | https://conductscience.org/library/papers/36408920 | PubMed |
| 19 | 33902106 | Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. | Nature | 2021 | https://conductscience.org/library/papers/33902106 | PubMed |
| 20 | 35158892 | Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35158892 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42162629 | N6-methyladenosine modification in the context of viral infection: from molecular mechanism to therapeutic potential. | Virus Res | 2026 | https://conductscience.org/library/papers/42162629 | PubMed |
| 41952207 | METTL16 promotes MASLD progression through the regulation of lipid synthesis and immune response. | Biol Direct | 2026 | https://conductscience.org/library/papers/41952207 | PubMed |
| 41938016 | Recent advances in m6A RNA modification in hepatocellular carcinoma: from mechanisms to therapeutic potential. | Front Mol Biosci | 2026 | https://conductscience.org/library/papers/41938016 | PubMed |
| 41852637 | The Future of Epigenetics: Emerging Technologies and Clinical Applications. | ACS Pharmacol Transl Sci | 2026 | https://conductscience.org/library/papers/41852637 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| METTL1 | 4234 | PubTator's text mining | https://conductscience.org/library/genes/4234 | NCBI Gene |
| METTL16 | 79066 | PubTator's text mining | https://conductscience.org/library/genes/79066 | NCBI Gene |
| METTL18 | 92342 | PubTator's text mining | https://conductscience.org/library/genes/92342 | NCBI Gene |
| METTL3 | 56339 | PubTator's text mining | https://conductscience.org/library/genes/56339 | NCBI Gene |
| METTL6 | 131965 | PubTator's text mining | https://conductscience.org/library/genes/131965 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41006418
GET https://conductscience.org/api/papers/v1/41006418/references?page=2